Bulk Pharmaceutical API Sources for FOSINOPRIL SODIUM

Bulk Pharmaceutical API Sources for FOSINOPRIL SODIUM

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		23681451
ISpharm		I01-1155
Hangzhou APIChem Technology		AC-6227
ChemMol		30103132
ChemMol		49404523
Amadis Chemical		A842989
Oakwood Products		079501

Bulk Active Pharmaceutical Ingredient (API) Sources for Fosinopril Sodium

Last updated: February 19, 2026

This report identifies and analyzes key manufacturers and suppliers of bulk active pharmaceutical ingredient (API) fosinopril sodium. It details market players, their production capabilities, quality certifications, and geographic reach, providing essential data for procurement and R&D professionals in the pharmaceutical industry.

Who are the primary global manufacturers of fosinopril sodium API?

The global supply of fosinopril sodium API is concentrated among a select group of manufacturers, primarily located in Asia, with significant presence in India and China. These companies specialize in the synthesis and large-scale production of the API.

Key manufacturers include:

• Divi’s Laboratories Limited: Based in India, Divi's is a major API producer with significant capacity for various therapeutic areas, including cardiovascular drugs.
• Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical company, Dr. Reddy's manufactures a range of APIs, including those for antihypertensive medications.
• Lupin Limited: Headquartered in India, Lupin is a global pharmaceutical player with API manufacturing facilities that supply its finished dosage forms and the broader market.
• Hubei Biocause Pharmaceutical Co., Ltd.: A Chinese manufacturer that produces a diverse portfolio of APIs, including cardiovascular agents.
• Jiangsu Hengrui Pharmaceutical Co., Ltd.: Also based in China, Hengrui is a significant pharmaceutical enterprise with API manufacturing capabilities.

These companies operate large-scale, multi-purpose manufacturing plants designed to meet global regulatory standards. Their production is supported by robust R&D capabilities and a focus on process optimization to ensure cost-effectiveness and consistent quality.

What are the regulatory and quality certifications held by these API suppliers?

Compliance with international pharmaceutical quality standards is critical for API suppliers. Fosinopril sodium API intended for regulated markets must meet stringent requirements set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

Key certifications and compliance aspects for fosinopril sodium API suppliers include:

• Current Good Manufacturing Practices (cGMP): All reputable API manufacturers adhere to cGMP guidelines. This ensures that products are consistently produced and controlled according to quality standards appropriate for their intended use and as required by the marketing authorization. Facilities undergo regular inspections by regulatory authorities.
• Drug Master Files (DMFs): Suppliers typically file DMFs with regulatory agencies like the FDA. A DMF is a submission to the FDA that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their marketing applications without having direct access to the proprietary information.
• Certificate of Suitability to the European Pharmacopoeia (CEP): For products intended for the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) is often required. This demonstrates that the API complies with the relevant European Pharmacopoeia monograph.
• ISO Certifications: Many manufacturers also hold ISO 9001 (Quality Management Systems) and ISO 14001 (Environmental Management Systems) certifications, indicating a commitment to quality and sustainable practices.

For instance, Divi’s Laboratories has a history of successful FDA inspections and maintains DMFs for its key APIs. Similarly, Dr. Reddy's Laboratories and Lupin Limited have extensive portfolios of DMFs and CEPs for their API offerings, facilitating their global market access.

What is the typical production capacity and scale of these fosinopril sodium API manufacturers?

The production capacity for fosinopril sodium API varies among manufacturers, but leading players possess the infrastructure to produce metric tons annually. This scale is necessary to meet the demand for both generic and branded fosinopril sodium-containing finished drug products globally.

• Divi’s Laboratories: Has demonstrated large-scale API production capabilities, often operating multiple manufacturing sites. While specific numbers for fosinopril sodium are proprietary, their overall API output capacity is substantial, measured in thousands of metric tons across their product range.
• Dr. Reddy’s Laboratories: Operates cGMP-compliant manufacturing facilities with significant capacity for complex APIs, including cardiovascular agents. Their production scale is geared towards supporting a global pharmaceutical supply chain.
• Lupin Limited: Possesses dedicated API manufacturing sites equipped with modern technology to achieve high-volume production. Their capacity is structured to support their own vertically integrated operations and external sales.

Manufacturers invest in advanced synthesis technologies and process automation to optimize yields, reduce production cycles, and maintain cost competitiveness. The ability to scale production rapidly in response to market demand is a key characteristic of these suppliers.

What are the key quality parameters and specifications for fosinopril sodium API?

Fosinopril sodium API must meet strict pharmacopoeial standards to ensure its safety and efficacy in finished pharmaceutical products. The primary reference standards are typically the United States Pharmacopoeia (USP) and the European Pharmacopoeia (Ph. Eur.).

Key quality parameters and specifications include:

• Assay: The content of fosinopril sodium is typically specified to be not less than 98.0% and not more than 102.0% of C21H22N O5PNa, calculated on the dried basis.
• Identification: Tests to confirm the identity of the substance, often involving Infrared (IR) spectroscopy and High-Performance Liquid Chromatography (HPLC) retention times matching reference standards.
• Related Substances/Impurities: Strict limits are placed on impurities, including process-related impurities and degradation products. These are usually controlled to very low levels (e.g., individual unspecified impurities not more than 0.10%, total impurities not more than 0.5% or 1.0%). Specific impurities may have defined limits.
• Water Content: Typically determined by Karl Fischer titration, with a specified limit, for example, not more than 1.0%.
• Residue on Ignition (Sulfated Ash): A measure of inorganic impurities, with a specified limit, such as not more than 0.1%.
• Heavy Metals: Limits are set for heavy metals contamination, usually not more than 10 ppm or 20 ppm.
• Residual Solvents: Levels of residual organic solvents used in the manufacturing process must comply with International Council for Harmonisation (ICH) Q3C guidelines.
• Chirality: Fosinopril sodium is a chiral molecule. While the marketed product is typically a racemic mixture, specifications may address enantiomeric purity if a specific stereoisomer is targeted or to control specific impurities. The structure of fosinopril is (±)-[(RS)-2-[[(RS)-1-cyclohexyl-1-hydroxy-1-phenylmethyl]phosphinoyl]phenyl]propanoic acid sodium salt.
• Physical Characteristics: Appearance (e.g., white to off-white crystalline powder), solubility, and particle size distribution may also be specified depending on the end-use requirements.

Manufacturers provide a Certificate of Analysis (CoA) with each batch, detailing the test results against these specified parameters.

What is the competitive landscape and market outlook for fosinopril sodium API?

The market for fosinopril sodium API is characterized by the presence of established generic API manufacturers. The primary drivers for demand are the ongoing use of fosinopril sodium in treating hypertension and its inclusion in combination therapies.

• Competition: Competition is primarily based on price, quality, regulatory compliance, and reliability of supply. Manufacturers in India and China generally offer competitive pricing due to lower manufacturing costs and economies of scale.
• Generic Market Dominance: Fosinopril sodium is a well-established drug with its patent protection long expired in most major markets. The API market is therefore largely driven by generic pharmaceutical manufacturers.
• Market Outlook: The market for fosinopril sodium API is expected to remain stable. While newer antihypertensive agents may gain market share, fosinopril sodium continues to be prescribed due to its efficacy and established safety profile, particularly in specific patient populations and combination therapies. The demand for generic APIs generally correlates with the global demand for generic finished drug products.
• Supply Chain Considerations: Pharmaceutical companies sourcing fosinopril sodium API need to consider supply chain resilience. This involves qualifying multiple suppliers, assessing geopolitical risks, and ensuring consistent quality and regulatory adherence from their chosen partners. The increasing emphasis on supply chain security post-pandemic may lead to diversification strategies among API purchasers.
• Pricing Trends: API pricing is influenced by raw material costs, manufacturing efficiencies, regulatory compliance overhead, and market competition. While prices for mature APIs like fosinopril sodium are generally stable, they can fluctuate based on these factors.

How does fosinopril sodium API compare to other ACE inhibitor APIs?

Fosinopril sodium is an angiotensin-converting enzyme (ACE) inhibitor. It belongs to a class of drugs widely used for treating hypertension, heart failure, and certain kidney diseases. Comparing fosinopril sodium to other ACE inhibitors highlights its unique properties and market position.

Key ACE inhibitors and their comparative aspects:

Feature	Fosinopril Sodium	Enalapril Maleate	Lisinopril	Ramipril
Class	ACE Inhibitor	ACE Inhibitor	ACE Inhibitor	ACE Inhibitor
Prodrug Status	Prodrug (metabolized to active fosinopril)	Prodrug (metabolized to active enalaprilat)	Active drug	Prodrug (metabolized to active ramiprilat)
Metabolism	Hepatic and renal elimination	Primarily renal excretion	Primarily renal excretion	Hepatic metabolism followed by renal excretion
Half-life	Approximately 14 hours (active metabolite)	Approximately 11 hours (active metabolite)	Approximately 12 hours	Approximately 13-15 hours (active metabolite)
Excretion	Renal and biliary	Renal	Renal	Renal and biliary
Indications	Hypertension, Heart Failure	Hypertension, Heart Failure, Asymptomatic LV dysfunction	Hypertension, Heart Failure, Post-MI	Hypertension, Heart Failure, Post-MI
API Manufacturing	Requires specific synthesis routes, controlled impurities.	Common API, widely produced globally.	Common API, widely produced globally.	Common API, widely produced globally.
Market Share	Significant, but often shares market with other ACEIs.	One of the most widely prescribed ACEIs.	High market share, popular for chronic use.	Strong market presence, particularly in cardiovascular prevention.
Key Differentiator	Dual hepatic/renal elimination offers an advantage in patients with impaired renal function.	Well-established, cost-effective.	Active drug simplifies dosing for some patients.	Effective in reducing cardiovascular events.

Fosinopril sodium’s unique advantage lies in its dual pathway of elimination (renal and hepatic), which can be beneficial for patients with compromised kidney function, unlike some other ACE inhibitors that are primarily renally excreted. This characteristic can influence prescribing decisions in specific patient profiles. From an API sourcing perspective, the manufacturing complexity and impurity profiles can differ, impacting production costs and regulatory hurdles for each specific ACE inhibitor API.

What are the future trends impacting the fosinopril sodium API market?

Several trends are shaping the future landscape for fosinopril sodium API and the broader pharmaceutical API market.

• Increasing Demand for Generic APIs: The global trend towards cost containment in healthcare continues to drive demand for generic pharmaceuticals, and consequently, for generic APIs like fosinopril sodium.
• Regulatory Scrutiny: Regulatory agencies worldwide are intensifying their oversight of API manufacturing. This includes more frequent inspections, stricter enforcement of cGMP, and enhanced requirements for impurity profiling and data integrity. Suppliers must maintain robust quality systems to meet these evolving standards.
• Supply Chain Diversification: Geopolitical events and past supply chain disruptions have prompted pharmaceutical companies to seek greater supply chain resilience. This may lead to a diversification of API sourcing away from single regions or suppliers, potentially creating opportunities for manufacturers in different geographies.
• Advancements in Synthesis and Manufacturing Technology: Continuous innovation in chemical synthesis, process analytical technology (PAT), and continuous manufacturing could lead to more efficient, cost-effective, and environmentally friendly production of fosinopril sodium API.
• Focus on Sustainability: Growing environmental consciousness and regulatory pressures are pushing API manufacturers towards greener chemistry and sustainable manufacturing practices, including waste reduction, solvent recycling, and energy efficiency.

These trends will influence sourcing strategies, supplier selection criteria, and the overall dynamics of the fosinopril sodium API market.

Key Takeaways

The global supply of fosinopril sodium API is dominated by established manufacturers in India and China, including Divi’s Laboratories, Dr. Reddy’s Laboratories, and Lupin Limited. These suppliers operate under strict cGMP regulations and maintain necessary certifications such as DMFs and CEPs for market access. Production capacities are significant, enabling multi-ton annual output. Quality specifications, guided by pharmacopoeial standards (USP, Ph. Eur.), focus on assay, impurities, water content, and residual solvents. The market is mature and driven by generic demand, with competition centered on price, quality, and regulatory compliance. Fosinopril sodium's dual hepatic/renal elimination pathway differentiates it among ACE inhibitors. Future market dynamics will be shaped by increasing generic demand, heightened regulatory scrutiny, supply chain diversification efforts, and technological advancements in manufacturing.

Frequently Asked Questions

1. Are there any novel synthesis routes emerging for fosinopril sodium API that could impact cost or quality? While established synthesis routes are prevalent, ongoing R&D in process chemistry for existing APIs can lead to optimizations. However, no widely disruptive novel routes for fosinopril sodium API have been publicly announced that would significantly alter the current market structure in the short term. Manufacturers continually refine their processes to improve yield and reduce impurities, which constitutes incremental innovation.

2. What are the typical lead times for ordering bulk fosinopril sodium API from major suppliers? Lead times for bulk fosinopril sodium API can vary based on the supplier’s current production schedule, order volume, and geographical location of the buyer. Generally, for established products with consistent demand, lead times can range from 4 to 12 weeks from order placement to delivery. Larger, strategic orders may involve longer planning horizons.

3. How do regulatory changes in impurity profiling (e.g., nitrosamine concerns) affect fosinopril sodium API sourcing? While nitrosamine impurities have been a focus for certain drug classes, the specific structural characteristics of fosinopril sodium and its common synthesis routes do not inherently make it susceptible to nitrosamine formation in the same manner as drugs containing specific chemical linkages. However, all API manufacturers must maintain robust impurity control strategies to comply with evolving regulatory expectations, including thorough risk assessments for all potential impurity classes.

4. What is the impact of the dual hepatic and renal excretion of fosinopril on API selection and formulation? The dual elimination pathway of fosinopril offers therapeutic advantages in patients with renal impairment, potentially reducing the need for dose adjustments compared to primarily renally cleared ACE inhibitors. For API selection, this means that suppliers with consistent quality and reliable supply can be critical for manufacturers targeting broad patient populations. For formulation, this characteristic generally does not impose unique API quality requirements beyond standard pharmacopoeial specifications, but it reinforces the drug's established therapeutic niche.

5. Can fosinopril sodium API be sourced from manufacturers outside of India and China? While India and China are the predominant manufacturing hubs for fosinopril sodium API due to cost-effectiveness and large-scale capacity, some API manufacturers in other regions, including Europe and North America, may also produce it, particularly if they specialize in niche or high-value APIs, or if driven by regional supply chain diversification initiatives. However, the volume and price competitiveness typically favor Asian producers for this specific API.

Citations

[1] United States Pharmacopeial Convention. (n.d.). USP General Chapter <1078> Good Manufacturing Practices for Bulk Pharmaceutical Excipients. Retrieved from USP website. (Note: Specific USP monographs for Fosinopril Sodium would also be referenced in a detailed analytical report).

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia. Retrieved from EDQM website. (Note: Specific Ph. Eur. monographs for Fosinopril Sodium would also be referenced).

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019). ICH Harmonised Tripartite Guideline M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.

[4] Divi’s Laboratories Limited. (n.d.). Products Overview. Retrieved from Divi's Laboratories website.

[5] Dr. Reddy’s Laboratories. (n.d.). API Portfolio. Retrieved from Dr. Reddy's Laboratories website.

[6] Lupin Limited. (n.d.). API Business. Retrieved from Lupin Limited website.